These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29777571)

  • 1. Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A.
    Batty P; Hart DP; Platton S
    Int J Lab Hematol; 2018 Oct; 40(5):561-568. PubMed ID: 29777571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.
    Boylan B; Miller CH
    Haemophilia; 2018 May; 24(3):487-491. PubMed ID: 29461004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.
    Gandhi T; Lawler P; Foxton E; Chowdary P; Riddell A
    Haemophilia; 2020 Nov; 26(6):e300-e307. PubMed ID: 32892451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
    Batty P; Riddell A; Kitchen S; Sardo Infirri S; Walker I; Woods T; Jennings I; Hart DP
    Haemophilia; 2021 May; 27(3):490-499. PubMed ID: 33650732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
    Millner AH; Tiefenbacher S; Robinson M; Boesen HT
    Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lupus anticoagulants in immediate acting inhibitor positivity in congenital haemophilia A patients.
    Patil R; S C; Parihar A; Mohite A; Shetty S
    Thromb Res; 2018 Dec; 172():29-35. PubMed ID: 30359788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Rapid and Fully Automated Factor VIII-Inhibitor Assay, Insensitive for Emicizumab, and a Lowest Level of Quantification of 0.2BU/mL.
    Verbruggen B; Binder NB; van Velp PJC; Polenewen R; Knöbl P; Sobas F; Moore GW
    J Thromb Haemost; 2024 Jul; ():. PubMed ID: 38992344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
    Houissa B; Mliki ML; Abdelkafi S; Bouslama M; Zaïer M; Mahjoub T; Kortas M; Ghachem L; Yacoub S
    Hamostaseologie; 2003 Aug; 23(3):144-8. PubMed ID: 12923586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of storage conditions for diluted working solutions of porcine factor VIII and performance of the Bethesda assay for the determination of antiporcine FVIII inhibitor titres.
    Winikoff R; Boulanger A; Robinson P; St-Louis J; Lacroix S; Rivard GE
    Haemophilia; 2003 Jan; 9(1):104-9. PubMed ID: 12558786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction.
    de Lima Montalvão SA; Tucunduva AC; de Almeida Sambo AL; De Paula EV; de Souza Medina S; Ozelo MC
    Thromb Res; 2015 Dec; 136(6):1280-4. PubMed ID: 26344704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired haemophilia syndrome: pathophysiology and therapy.
    Elezović I
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.